vs
Legence Corp.（LGN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Legence Corp.的1.1倍（$772.1M vs $708.0M），Revvity净利率更高（12.7% vs -0.1%，领先12.8%），Legence Corp.同比增速更快（26.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $137.4M）
Legence Corp是一家可持续建筑与脱碳解决方案服务商，主要提供能效优化、楼宇自动化系统设计、可再生能源整合及低碳改造服务，客户覆盖商业、工业、公共机构等领域，核心业务布局北美，助力客户降低运营成本、减少碳排放。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LGN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$708.0M
营收增速更快
LGN
高出20.4%
5.9%
净利率更高
RVTY
高出12.8%
-0.1%
自由现金流更多
RVTY
多$24.4M
$137.4M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.0M | $772.1M |
| 净利润 | $-576.0K | $98.4M |
| 毛利率 | 20.9% | — |
| 营业利润率 | 5.3% | 14.5% |
| 净利率 | -0.1% | 12.7% |
| 营收同比 | 26.2% | 5.9% |
| 净利润同比 | 46.8% | 3.9% |
| 每股收益（稀释后） | $-0.02 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGNRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $708.0M | $698.9M | ||
| Q2 25 | — | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $560.8M | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润LGNRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $-576.0K | $46.7M | ||
| Q2 25 | — | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $-1.1M | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率LGNRVTY
| Q4 25 | — | — | ||
| Q3 25 | 20.9% | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.1% | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率LGNRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 5.3% | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 4.8% | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率LGNRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | -0.1% | 6.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -0.2% | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）LGNRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $-0.02 | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $176.0M | $919.9M |
| 总债务越低越好 | $812.6M | — |
| 股东权益账面价值 | $387.9M | $7.3B |
| 总资产 | $2.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 2.10× | — |
8季度趋势，按日历期对齐
现金及短期投资LGNRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $176.0M | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务LGNRVTY
| Q4 25 | — | — | ||
| Q3 25 | $812.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LGNRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $387.9M | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产LGNRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | — | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
负债/权益比LGNRVTY
| Q4 25 | — | — | ||
| Q3 25 | 2.10× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $137.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 19.4% | 21.0% |
| 资本支出强度资本支出/营收 | 3.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流LGNRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $162.1M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流LGNRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $137.4M | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率LGNRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 19.4% | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度LGNRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 3.5% | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率LGNRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGN
| Installation And Fabrication | $408.7M | 58% |
| Engineering And Design | $110.9M | 16% |
| Program And Project Management | $101.2M | 14% |
| Maintenance And Service | $87.1M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
